Yibai Pharmaceutical announced that recently the company received an “Notice of Administrative Penalty” from the Guizhou Drug Administration. In August 2025, the company suspended production and sales of pediatric cough syrups due to related issues, and resumed in September. The investigation revealed that the company failed to comply with pharmaceutical production quality management regulations in various areas, such as inspection of excipients entering the factory. In view of factors such as the company's active corrections and other factors, it is proposed to be fined 700,000 yuan. The company has no objection to the penalty. The matter does not touch on major illegal forced delisting situations, and is not expected to have a significant impact on the current period's results.

Yibai Pharmaceutical announced that recently the company received an “Notice of Administrative Penalty” from the Guizhou Drug Administration. In August 2025, the company suspended production and sales of pediatric cough syrups due to related issues, and resumed in September. The investigation revealed that the company failed to comply with pharmaceutical production quality management regulations in various areas, such as inspection of excipients entering the factory. In view of factors such as the company's active corrections and other factors, it is proposed to be fined 700,000 yuan. The company has no objection to the penalty. The matter does not touch on major illegal forced delisting situations, and is not expected to have a significant impact on the current period's results.